Active Biotech at BIO 2006
Lund, Sweden - 4 April 2006 - Active Biotech (Stockholm: ACTI.ST) management will present at the BIO 2006 Annual International Convention in Chicago (USA) on Tuesday, 11 April at 9:45 am in Room A, McCormick Place South.
Sven Andréasson, President and CEO will provide an overview of Active Biotech's projects that address the areas of autoimmune/inflammatory diseases and cancers. The presentation will provide an update on the company's most advanced projects:
- laquinimod (in partnership with Teva Pharmaceutical Industries Ltd.) - an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis; and
- ANYARA - for use in cancer immunotherapy, with primary indications for non-small cell lung cancer and renal cancer.
In addition, the presentation will address other key projects that Active Biotech has in clinical development, including the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® (in partnership with Avidex Ltd.) primarily for RA.
Company management will be present at the BIO2006 Business Forum.
Attendees are also encouraged to visit the Active Biotech booth, #1763 in the Scandinavian Pavilion, to meet company representatives and learn more about Active Biotech.
Lund, Sweden, 4 April 2006
Active Biotech AB (publ)
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50